SCHEMBL4112786

SCHEMBL4112786

Cc1nn2c(-c3ccc(Cl)cc3F)c(-c3ccccc3C#N)cnc2c1C(=O)NN(C)c1ccccn1

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GABRA1 P14867 3/20 0.35
GABRG2 P18507 3/20 0.35
GABRB3 P28472 3/20 0.35
GABRA3 P34903 3/20 0.35
GABRA5 P31644 1/20 0.35
GRM4 Q14833 1/20 0.35
GRIN2B Q13224 1/20 0.33
FPR1 P21462 1/20 0.33
FPR2 P25090 1/20 0.33
PDE2A O00408 1/20 0.33
PDE10A Q9Y233 1/20 0.33
PYGL P06737 1/20 0.32
SPR P35270 1/20 0.31
HIF1A Q16665 1/20 0.31
GCGR P47871 1/20 0.31
KDM4E B2RXH2 1/20 0.31
ALDH1A1 P00352 1/20 0.31
HPGD P15428 1/20 0.31
KMT2A Q03164 1/20 0.31
NPSR1 Q6W5P4 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4114117 0.89 KMT2A (0.38) GABRA1GABRG2GABRB3GABRA3GABRA5
SCHEMBL4115866 0.89 GRIN2B (0.34) GRM4GRIN2BPDE2APDE10APYGL
SCHEMBL4116611 0.87 GABRA1 (0.35) GABRA1GABRG2GABRB3GABRA3GABRA5
SCHEMBL4109771 0.82 CNR1 (0.39) GABRA1GABRG2GABRB3GABRA3GABRA5
SCHEMBL4129733 0.80 PDE4B (0.37) GABRA1GABRG2GABRB3GABRA3GABRA5
SCHEMBL1754896 0.79 ALDH1A1 (0.33) GABRA1GABRG2GABRB3GABRA3GABRA5
SCHEMBL4115103 0.78 DGAT2 (0.40) FPR1FPR2SMN1; SMN2
SCHEMBL4115107 0.78 DGAT2 (0.40) FPR1FPR2SMN1; SMN2
SCHEMBL4108378 0.76 KDM4E (0.38) GABRA1GABRG2GABRB3GABRA3GABRA5
SCHEMBL4125327 0.75 GRIN2B (0.37) GRM4GRIN2BPDE2APDE10APYGL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8188097-B2 Pyrazolo[1,5-A]pyrimidine compounds MITSUBISHI TANABE PHARMA CORPORATION (JP) 2012-05-29 US disclosed
US-20090069298-A1 Pyrazolo[1,5-A]Pyrimidine Compounds TANABE SEIYAKU CO., LTD. (JP) 2009-03-12 US disclosed
EP-1945220-A1 PYRAZOLO[1,5-A]PYRIMIDINE COMPOUNDS AS CANNABINOID RECEPTOR ANTAGONISTS Mitsubishi Tanabe Pharma Corporation (JP) 2008-07-23 EP disclosed
WO-2007046548-A1 PYRAZOLO[1,5-A]PYRIMIDINE COMPOUNDS AS CANNABINOID RECEPTOR ANTAGONISTS MITSUBISHI TANABE PHARMA CORPORATION (JP) 2007-04-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090069298-A1 Pyrazolo[1,5-A]Pyrimidine Compounds RECQL, QTRT1, DPYD GABRA1 1096/4885GABRG2 2214/4885GABRB3 1818/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.